BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 15213095)

  • 1. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.
    Bradstock KF; Matthews JP; Lowenthal RM; Baxter H; Catalano J; Brighton T; Gill D; Eliadis P; Joshua D; Cannell P; Schwarer AP; Durrant S; Gillett A; Koutts J; Taylor K; Bashford J; Arthur C; Enno A; Dunlop L; Szer J; Leahy M; Juneja S; Young GA;
    Blood; 2005 Jan; 105(2):481-8. PubMed ID: 15213095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
    Lowenthal RM; Bradstock KF; Matthews JP; Bishop JF; Juneja S; Cobcroft R; Eliadis P; Enno A; Gill D; Herrmann RP; Manoharan A; Page FJ; Rooney KF; Rosenfeld D; Seldon M; Taylor KM; Wolf MM; Young GA
    Leuk Lymphoma; 1999 Aug; 34(5-6):501-10. PubMed ID: 10492073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
    Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M
    Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
    Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A
    Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
    Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
    Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
    Jehn U; Suciu S; Thomas X; Lefrère F; Muus P; Berneman Z; Marie JP; Adamo F; Fillet G; Nobile F; Ricciuti F; Leone G; Rizzoli V; Montanaro M; Beeldens F; Fazi P; Mandelli F; Willemze R; de Witte T; Amadori S
    Leukemia; 2006 Oct; 20(10):1723-30. PubMed ID: 16932345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
    Bishop JF; Matthews JP; Young GA; Szer J; Gillett A; Joshua D; Bradstock K; Enno A; Wolf MM; Fox R; Cobcroft R; Herrmann R; Van Der Weyden M; Lowenthal RM; Page F; Garson OM; Juneja S
    Blood; 1996 Mar; 87(5):1710-7. PubMed ID: 8634416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
    Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
    Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
    Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
    Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
    Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
    Bradstock KF; Link E; Di Iulio J; Szer J; Marlton P; Wei AH; Enno A; Schwarer A; Lewis ID; D'Rozario J; Coyle L; Cull G; Campbell P; Leahy MF; Hahn U; Cannell P; Tiley C; Lowenthal RM; Moore J; Cartwright K; Cunningham I; Taper J; Grigg A; Roberts AW; Benson W; Hertzberg M; Deveridge S; Rowlings P; Mills AK; Gill D; Bardy P; Campbell L; Seymour JF;
    J Clin Oncol; 2017 May; 35(15):1678-1685. PubMed ID: 28368672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin.
    Seipelt G; Hofmann WK; Martin H; Wassmann B; Boehme A; Ottmann OG; Hoelzer D
    Ann Hematol; 1998; 76(3-4):145-51. PubMed ID: 9619732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.
    Bow EJ; Sutherland JA; Kilpatrick MG; Williams GJ; Clinch JJ; Shore TB; Rubinger M; Schacter BA
    J Clin Oncol; 1996 Apr; 14(4):1345-52. PubMed ID: 8648393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy.
    Mehta J; Powles R; Treleaven J; Swansbury GJ; Kulkarni S; Saso R; Min T; Singhal S
    Leuk Lymphoma; 1999 Aug; 34(5-6):553-60. PubMed ID: 10492079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
    Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.